Effect of Switching Basal Insulin Regimen to Degludec on Quality of Life in Japanese Patients with Type 1 and Type 2 Diabetes Mellitus

Overview

Journal J Pharm Health Care Sci

Publisher Biomed Central

Specialty Pharmacology

Date 2016 Jan 29

PMID 26819737

Citations 3

Authors

Morihiro Okada

Masae Okada

Jun Nishigami

Naoto Yamaaki

Kenji Furukawa

Kiminori Ohyama

Tsutomu Shimada

Yoshimichi Sai

Affiliations

Soon will be listed here.

Abstract

Background: Maintainance of a stable basal insulin level is important for glycemic control in treatment of diabetes mellitus. Recently introduced insulin degludec has the longest duration of action among basal insulin formulations. The purpose of this study was to assess changes in quality of life (QOL) associated with switching the basal insulin regimen to degludec in patients with type 1 and type 2 diabetes mellitus.

Methods: This 24-week open-label intervention study included type 1 (n = 10) and type 2 (n = 20) diabetes mellitus patients, with adequately controlled hemoglobin A1c (HbA1c), who had received insulin glargine or detemir for at least 6 months. The primary outcome was change of QOL from baseline, as assessed by the Diabetes Therapy-Related QOL (DTR-QOL) application, after switching from glargine or detemir to degludec. HbA1c and other parameters were also assessed as secondary outcomes.

Results: QOL and HbA1c in patients with type 1 diabetes mellitus were unchanged during this study. In patients with type 2 diabetes mellitus, HbA1c did not change, but total DTR-QOL score was significantly improved from baseline after switching to degludec. The DTR-QOL Factor 2, "Anxiety and dissatisfaction with treatment", was significantly improved in patients with type 2 diabetes mellitus and especially in the subgroup receiving basal supported oral therapy (BOT).

Conclusions: Switching of the basal insulin regimen from glargine or detemir to degludec significantly improved the QOL of patients with type 2 diabetes mellitus who were receiving BOT, by reducing mental stress or anxiety about their treatment.

Citing Articles

The revalidation of the diabetes treatment-related quality-of-life (DTR-QOL) questionnaire in Japan.

Ishii H, Kim H, Crawford B Diabetol Int. 2019; 10(2):93-101.

PMID: 31139527 PMC: 6506486. DOI: 10.1007/s13340-018-0371-1.

Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan.

Tanaka N, Yabe D, Murotani K, Ueno S, Kuwata H, Hamamoto Y J Diabetes Investig. 2018; 9(5):1203-1211.

PMID: 29493881 PMC: 6123045. DOI: 10.1111/jdi.12827.

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.

Kaku K, Wolden M, Hyllested-Winge J, Nortoft E Diabetes Ther. 2017; 8(1):189-195.

PMID: 28091878 PMC: 5306124. DOI: 10.1007/s13300-017-0225-z.

References

Heise T, Nosek L, Bottcher S, Hastrup H, Haahr H . Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012; 14(10):944-50. DOI: 10.1111/j.1463-1326.2012.01638.x. View

Porcellati F, Rossetti P, Busciantella N, Marzotti S, Lucidi P, Luzio S . Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007; 30(10):2447-52. DOI: 10.2337/dc07-0002. View

Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard D, Wahlund P, Ribel U . Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012; 29(8):2104-14. PMC: 3399081. DOI: 10.1007/s11095-012-0739-z. View

Oyer D, Narendran P, Qvist M, Niemeyer M, Nadeau D . Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses. Expert Opin Drug Deliv. 2011; 8(10):1259-69. DOI: 10.1517/17425247.2011.615830. View

Mashitani T, Hayashino Y, Okamura S, Kitatani M, Furuya M, Iburi T . Diabetes treatment-related quality of life is associated with levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 8). Acta Diabetol. 2015; 52(4):639-47. DOI: 10.1007/s00592-015-0725-0. View

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L . Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1489-97. DOI: 10.1016/S0140-6736(12)60204-9. View

Dhatt G, Agarwal M, Bishawi B . HbA1c: a comparison of NGSP with IFCC transformed values. Clin Chim Acta. 2005; 358(1-2):81-6. DOI: 10.1016/j.cccn.2005.02.009. View

Davies M, Gross J, Ono Y, Sasaki T, Bantwal G, Gall M . Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014; 16(10):922-30. PMC: 4237553. DOI: 10.1111/dom.12298. View

Bailey T, Thurman J, Niemeyer M, Schmeisl G . Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals. Curr Med Res Opin. 2011; 27(10):2043-52. DOI: 10.1185/03007995.2011.616190. View

10.

Garg S, Bailey T, DeLuzio T, Pollom D . Preference for a new prefilled insulin pen compared with the original pen. Curr Med Res Opin. 2011; 27(12):2323-33. DOI: 10.1185/03007995.2011.630721. View

11.

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard H, Johansen T . Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12):2464-71. PMC: 3507614. DOI: 10.2337/dc12-1205. View

12.

Koehler G, Treiber G, Wutte A, Korsatko S, Mader J, Semlitsch B . Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab. 2013; 16(1):57-62. DOI: 10.1111/dom.12178. View

13.

Meneghini L, Atkin S, Gough S, Raz I, Blonde L, Shestakova M . The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in.... Diabetes Care. 2013; 36(4):858-64. PMC: 3609505. DOI: 10.2337/dc12-1668. View

14.

Ishii H . Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. J Med Econ. 2012; 15(3):556-63. DOI: 10.3111/13696998.2012.665111. View